作者: Kazuki Yokota , Naoya Igaki
DOI: 10.2169/INTERNALMEDICINE.51.7592
关键词:
摘要: A dipeptidyl peptidase (DPP)-4 inhibitor, commonly used to treat patients with type 2 diabetes, has caused concern because of immune system side effects. We report a 48-year-old woman diabetes who was diagnosed rheumatoid arthritis (RA) after continued polyarthritis and an increase in factor up 86 IU/mL three months treatment sitagliptin, DPP-4 inhibitor. The shared epitope (SE)-containing human leukocyte antigen (HLA)-DRB1 alleles, which are important predisposing factors for RA, were positive. RA might have been triggered by sitagliptin due condition.